Author Topic: Tysabri-related PML cases  (Read 27 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 7379
  • Location: Pacific Northwest
Tysabri-related PML cases
« on: March 26, 2017, 01:51:38 pm »
New data reveal that as of March 6, 2017, there have been 714 confirmed Tysabri-related PML cases worldwide, with 711 of them in persons with MS and 3 in persons with Crohn's disease.

As of February 28, 2017, overall PML incidence was 4.20 per 1000 patients (95% CI 3.89 to 4.52 per 1000 patients). 23% of the patients have died; 77% of patients are alive with varying levels of disability.

As of February 28, 2017, approximately 167,300 patients received Tysabri in a post-marketing setting, worldwide.
« Last Edit: June 26, 2017, 12:17:12 pm by agate »





SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline ssalimi

  • Posts: 9
711 cases of Tysabri-related PML in persons w/MS
« Reply #1 on: April 02, 2017, 02:30:21 pm »
What was the source for this?
« Last Edit: April 02, 2017, 02:37:14 pm by ssalimi »

Offline agate

  • Administrator
  • *****
  • Posts: 7379
  • Location: Pacific Northwest
Re: 711 cases of Tysabri-related PML in persons w/MS
« Reply #2 on: April 02, 2017, 03:28:06 pm »
https://chefarztfrau.de/?page_id=716

This is an unofficial source but apparently this guy (named Alexander Otto) in Germany has access to the correct information because he's been posting the data correctly for many years.
« Last Edit: April 03, 2017, 07:08:52 am by agate »





SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 7379
  • Location: Pacific Northwest
718 PML cases for PwMS as of 6/6/17, 24% have died
« Reply #3 on: June 26, 2017, 12:14:18 pm »
Updated, from the same source
:
Quote
As of June 06. 2017, there have been 731 (728 MS, 3 CD) confirmed PML cases worldwide.

As of May 31, 2017, overall PML incidence: 4.21 per 1000 patients (95% CI 3.91 to 4.52 per 1000 patients). 24% of patients have died; 76% of patients are alive with varying levels of disability.
As of May 31, 2017, approximately 170,900 patients received natalizumab in post-marketing setting worldwide.





SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
41 Views
Last post April 13, 2016, 02:06:25 pm
by agate
0 Replies
27 Views
Last post July 14, 2016, 08:51:48 am
by agate
0 Replies
35 Views
Last post December 12, 2016, 03:31:46 pm
by agate
0 Replies
29 Views
Last post December 22, 2016, 06:00:29 pm
by agate
0 Replies
12 Views
Last post February 24, 2017, 11:15:22 am
by agate